Arguments against Monitoring Levels of Anti-Factor Xa in Conjunction with Low-Molecular-Weight Heparin Therapy
نویسندگان
چکیده
The product monographs for some low-molecular-weight heparins (LMWHs) state that anti-factor Xa concentrations should be monitored in the treatment of deep vein thrombosis. This article reviews the pharmacological and epidemiological basis for this recommendation and finds the evidence wanting. Anti-factor Xa activity varies for each LMWH, and evidence from clinical trials using anti-factor Xa monitoring does not support a link between activity of anti-factor Xa, bleeding, and effect of the drug. Given this lack of evidence, routine monitoring of anti-factor Xa in conjunction with LMWH therapy is not recommended.
منابع مشابه
Routine coagulation assays underestimate levels of antithrombin-dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis.
There is increasing recognition that thrombotic complications may occur in patients with cirrhosis, and literature on antithrombotic treatment in these patients is rapidly emerging. Due to extensive haemostatic changes in patients with cirrhosis, careful monitoring of anticoagulant therapy may be required. Recent data suggest that plasma levels of low molecular weight heparin (LMWH) are substan...
متن کاملLack of correlation between heparin dose and standard clinical monitoring tests in treatment with unfractionated heparin in critically ill children.
UNLABELLED The activated partial thromboplastin time (aPTT) and anti-Xa activity are used for monitoring unfractionated heparin (UFH) therapy in children and may not be optimal. OBJECTIVE Determine correlations of aPTT, anti-Xa and UFH dose in children. Single centre prospective cohort study in children receiving UFH. The aPTT and anti-Xa results from routine coagulation monitoring were colle...
متن کاملAdequate thromboprophylaxis in critically ill patients
Venous thromboembolism is a relatively frequently occurring complication in critically ill patients admitted to the ICU despite prophylactic treatment with subcutaneous low molecular weight heparin. Several studies show that critically ill patients have significantly lower plasma anti-factor-Xa activity levels compared to control patients after administration of subcutaneous heparin. Robinson a...
متن کاملEstablishing the heparin therapeutic range using aPTT and anti-Xa measurements for monitoring unfractionated heparin therapy
BACKGROUND Unfractionated heparin (UFH) has unstable pharmacokinetics and requires close monitoring. The activated partial thromboplastin time (aPTT) test has been used to monitor UFH therapy for decades in Korea, but its results can be affected by numerous variables. We established an aPTT heparin therapeutic range (HTR) corresponding to therapeutic anti-Xa levels for continuous intravenous UF...
متن کاملAnti Xa monitoring during treatment with low molecular weight heparin or danaparoid: inter-assay variability.
If laboratory monitoring of low molecular weight heparin (LMWH) therapy is required the test of choice is the anti Xa activity assay. The relationship between anti Xa results obtained using different techniques is unknown. The aim of the present study was to compare anti Xa results obtained with eight different commercially available anti Xa activity assays (five chromogenic and three clotting ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2009